Protego Biopharma closed an oversubscribed $130 million financing to advance its first‑in‑class oral program for light‑chain (AL) amyloidosis into a potential pivotal study next year. The round was led by Novartis Venture Fund and Forbion with participation from Omega Funds, Droia Ventures, YK Bioventures, Digitalis Ventures and returning investors. The company says the cash runway supports initiation of a pivotal test in 2026. Protego’s lead candidate is an oral small molecule designed to stabilize misfolded light‑chain proteins that cause organ damage in AL amyloidosis. The company positions the approach as an alternative to antibody strategies that failed in recent pivotal trials from larger competitors. AL amyloidosis is a rare plasma‑cell disorder characterized by deposition of amyloid fibrils in organs, often requiring novel targeted agents. Investors backing Protego include experienced rare‑disease and venture groups; the financing aims to fund expanded clinical development and manufacturing scale‑up. Company statements and media coverage note the program’s potential to reach a pivotal endpoint next year and to re‑energize interest in small‑molecule stabilizers for amyloid diseases.